Skip to main content

Advertisement

Table 5 Univariate analysis of risk factors associated with growth failure amongst the Chinese patients in this study

From: Risk factors for damage in childhood-onset systemic lupus erythematosus in Asians: a case control study

Risk Factors No growth failure (n = 47) Growth failure (n = 9) p-value a
Patient demographics
 Age at diagnosis 13 [12–15] 10 [7.5–12.5] < 0.01
 Male 8 (17%) 1 (11.1%) 1.00
 Disease duration (year) 8.2 [5.5–11.1] 9.3 [5.85–12.5] 0.45
Laboratory data at diagnosis
 Haemoglobin (g/dL) 10.6 [9.5–11.9] 10.55 [9.7–11.5] 0.73
 White cell count (×109/L) 4 [3.4–6.7] 6 [3.7–6.9] 0.14
 Platelet (×109/L) 183 [100.5–265.0] 198.5 [87.8–261.8] 0.84
 Serum albumin (g/L) 35 [30.5–40.0] 37 [32.3–38.8] 0.87
 Serum creatinine (umol/L) 55 [50.0–68.5] 52 [43.3–55.5] 0.28
 C3 (g/L) 0.48 [0.3–0.7] 0.39 [0.3–0.5] 0.1
 C4 (g/L) 0.09 [0.05–0.12] 0.05[0.04–0.08] 0.25
 Anti-dsDNA titre (IU/mL) 300 [77–300] 300 [181–300] 0.34
 SLEDAI score at diagnosis 12 [8–15] 11 [9–13] 0.72
Disease manifestations over the course of the study period
 Neuropsychiatric manifestations 5 (10.6%) 3 (33.3%) 0.11
 Haematological involvement 32 (68.1%) 5 (55.6%) 0.47
 Renal involvement 36 (76.6%) 8 (88.9%) 0.67
 Serositis 8 (17%) 1 (11.1%) 1.00
 Number of major organ involvement 1 [1–2] 2 [1–2.5] 0.64
Treatment related factors
 Cumulative dose of CYC (mg/kg) 27.5 [0–140] 79 [0–121.5] 0.79
 Ever use of CYC 26 (55.3%) 7 (77.8%) 0.28
 Ever use of intravenous MP 21 (44.7%) 5 (55.6%) 0.72
Events during course of disease
 Number of lupus flares 2 [0–6] 4 [1–6] 0.33
 Episodes of major infection 1 [0–2] 1 [0.5–1.5] 0.37
  1. Descriptive data represented as median [interquartile range] or frequency (%)
  2. Statistically significant variables are highlighted as bold text
  3. SLEDAI SLE disease activity index, CYC cyclophosphamide, MP methylprednisolone
  4. a Calculated with Fisher’s exact test or Mann-Whitney U test